Carl J. Danzig, MD | Image Credit: Rand Eye Institute
A recent study reaffirmed the safety and efficacy of using faricimab to treat macular edema due to retinal vein occlusion (RVO) by reducing vascular endothelial growth factor (VEGF). The study was a secondary phase of the BALATON and COMINO trials, which met their primary endpoints of faricimab noninferiority to aflibercept at week 24.1
These sustained increases seen with faricimab have not been seen in earlier central/hemiretinal RVO anti-VEGF trials. The COPERNICUS trial in particular exhibited diminished anatomic and visual improvements over the course of weeks 24 to 52.2
“To our knowledge, this report from BALATON/COMINO is the first to document vision and anatomical improvements have been maintained for more than 1 year in a global, randomized, phase 3 study in…